Abstract 420P
Background
KRAS mutations define a molecular subgroup of non-small cell lung cancer (NSCLC). KRAS G12C mutations can be targeted by small molecule inhibitors. Further investigation of cellular and molecular components of KRASm NSCLC is warranted to understand the disease mechanisms and guide precise treatment.
Methods
Tumor specimens of KRASm NSCLC were histologically evaluated, DNA and RNA were extracted. Comprehensive genomic and transcriptomic profiling were detected by Illumina TruSight Oncology 500 kit and TruSeq RNA Exome kit. Correlation analysis included demographic and clinical data as well.
Results
Among 162 cases of KRASm NSCLC, there were 141 males and 21 females, 140 adenocarcinoma and 8 squamous cell carcinoma, 2 sarcoid carcinoma, 1 large cell carcinoma and 1 NOS, 121 smokers and 41 non-smokers. Using next-generation sequencing (NGS), C>T transition signatures were found most often, followed by C>A, T>C, C>G, T>G, and T>A. KRAS mutations included 68 G12Cs, 33 G12Ds, 32 G12Vs, 9 G12As, 6 G13Ds, 6 Q61H/Ls and others. Major co-altered genes included TP53, LRP1B, FAT1, STK11, ARID1B, PTPRD, SPTA1, NOTCH3, NOTCH1, MGA, KEAP1, ZFHX3, etc. The genes co-alterations with KRAS were TP53 (59, 35.1%), followed by STK11 (27, 16.1%), STK11/TP53 (20, 11.9%), CDKN2A/TP53 (7, 4.2%), CDKN2A/STK11 (4, 3.4%) and CDKN2A/STK11/TP53 (3, 1.8%). Using MDACC's report, four groups were established: KL, KP, KC, and K-only. Correlation of genotypes with clinical outcome after adjuvant therapies will be analysed. Compared with adjacent tissues, KRASm cancer tissues had differentially expressed genes (DEGs) enriched in pathways of cytokine receptor interaction, primary immunodeficiency, intestinal immune network for IgA production, and etc. All KRAS tumors can be categorized into low and high inflamed groups by StromalScore, ImmuneScore and ESTIMATEScore methods.
Conclusions
Chinese KRAS mutant lung cancers are highly heterogeneous in terms of both KRAS mutations and co-altered genes and varied in inflammatory status in tumor microenvironment as well. Molecular and immune characteristics in KRASm NSCLC may influence the clinical outcome of adjuvant therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract